Authors: Olivia Stevenson (Future Science Group)
A research team from the NIH National Institute of Allergy and Infectious Diseases Rocky Mountain Laboratories (MT, USA) has developed what they anticipate is the first cerebral organoid system for studying sporadic Creutzfeldt–Jakob disease (CJD). This could be a promising means of assessing and developing potential CJD treatments in the future.
Organoids have been utilized to study diseases such as Zika and Alzheimer’s disease, however, this is the first cerebral organoid system for studying CJD. This model will hopefully enable investigators to evaluate potential therapeutics for CJD and provide greater detail about human prion disease subtypes than currently used models, such as rodents and nonhuman primates.